Achaogen Presents Data

Achaogen presented data that demonstrated the potential of plazomicin against multi-drug resistant gram-negative bacteria at the American Society for Microbiology meeting currently being held in New Orleans.

The Care trial presentation described the reduced mortality in patients with bloodstream infections receiving plazomicin compared to colistin at day 28 and through long term follow-up at day 60. Additionally, the company noted just prior to the meeting that the U.S. Food and Drug Administration granted plazomicin breakthrough therapy designation for the treatment of bloodstream infections caused by certain enterobacteriaceae.

Leave a Comment